Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 3 patents
8 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Rapid Publication Free access | 10.1172/JCI109655

Elevated Thromboxane Levels in the Rat during Endotoxic Shock: PROTECTIVE EFFECTS OF IMIDAZOLE, 13-AZAPROSTANOIC ACID, OR ESSENTIAL FATTY ACID DEFICIENCY

J. A. Cook, W. C. Wise, and P. V. Halushka

Department of Physiology, Medical University of South Carolina, Charleston, South Carolina 29403

Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29403

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29403

Find articles by Cook, J. in: PubMed | Google Scholar

Department of Physiology, Medical University of South Carolina, Charleston, South Carolina 29403

Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29403

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29403

Find articles by Wise, W. in: PubMed | Google Scholar

Department of Physiology, Medical University of South Carolina, Charleston, South Carolina 29403

Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29403

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29403

Find articles by Halushka, P. in: PubMed | Google Scholar

Published January 1, 1980 - More info

Published in Volume 65, Issue 1 on January 1, 1980
J Clin Invest. 1980;65(1):227–230. https://doi.org/10.1172/JCI109655.
© 1980 The American Society for Clinical Investigation
Published January 1, 1980 - Version history
View PDF
Abstract

The potential deleterious role of the proaggregatory vasoconstrictor, thromboxane A2, in endotoxic shock was investigated in rats. Plasma thromboxane A2 was determined by radioimmunoassay of its stable metabolite thromboxane B2. After intravenous administration of Salmonella enteritidis endotoxin (20 mg/kg), plasma thromboxane B2 levels increased from nondetectable levels (<375 pg/ml) in normal control rats to 2,054±524 pg/ml (n = 8), within 30 min to 2,071±429 at 60 min, and decreased to 1,119±319 pg/ml, at 120 min. Plasma levels of prostaglandin E also increased from 146±33 pg/ml in normal controls (n = 5) to 2,161±606 pg/ml 30 min after endotoxin (n = 5).

In contrast to shocked controls, rats pretreated with imidazole, a thromboxane synthetase inhibitor, or essential fatty acid-deficient rats, which are deficient in arachidonate and its metabolites, did not exhibit significant elevations in plasma levels of thromboxane B2. Imidazole did not however inhibit endotoxin-induced elevations in plasma prostaglandin E. Essential fatty acid deficiency significantly reduced mortality to lethal endotoxic shock. This refractoriness could be duplicated in normal rats pretreated with the fatty acid cyclo-oxygenase inhibitor, indomethacin (10 mg/kg), intravenously 30 min before endotoxin injection. Imidazole (30 mg/kg) administered intraperitoneally 1 h before or intravenously 30 min before endotoxin, also significantly (P < 0.01) reduced mortality from lethal endotoxin shock to 40% compared to a control mortality of 95% at 24 h. Likewise pretreatment with 13-azaprostanoic acid (30 mg/kg), a thromboxane antagonist, reduced mortality from endotoxic shock at 24 h from 100% in control rats to only 50% (P < 0.01). The results suggest that endotoxin induces increased synthesis of thromboxane A2 that may contribute to the pathogenesis of endotoxic shock.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 227
page 227
icon of scanned page 228
page 228
icon of scanned page 229
page 229
icon of scanned page 230
page 230
Version history
  • Version 1 (January 1, 1980): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 patents
8 readers on Mendeley
See more details